ATXS - NASDAQ

Astria Therapeutics, Inc.

Astria Therapeutics, Inc.

ATXSยทNASDAQ

$12.58

+0.0000%
HealthcareBiotechnology

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$718.13M
EPS-1.6800
P/E Ratio-7.49
Earnings Date03/10/2026
Astria Therapeutics, Inc.

Astria Therapeutics, Inc. Fair Value Envelope

ATXS ยท NASDAQ

Our analysis suggests that ATXS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $12.58, this represents a potential HIDDEN relative to our calculated worth for Astria Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $12.58

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$229.3M
+ Cash & Equivalents$59.8M
Firm Value-$169.5M
- Debt$5.4M
Equity Value-$174.8M
/ Shares Outstanding56,434,894B
DCF Value-$3
OVERVALUED BY 125%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$65.7M
-$53.2M
-$43.0M
-$34.8M
-$28.2M
-$22.8M
-$18.4M
-$14.9M
-$12.1M
-$9.8M
Maintenance CapEx
-$52.6K
-$42.6K
-$34.4K
-$27.9K
-$22.5K
-$18.2K
-$14.8K
-$11.9K
-$9.7K
-$7.8K
Owner Earnings
-$65.8M
-$53.2M
-$43.1M
-$34.8M
-$28.2M
-$22.8M
-$18.5M
-$14.9M
-$12.1M
-$9.8M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$60.9M
-$45.6M
-$34.2M
-$25.6M
-$19.2M
-$14.4M
-$10.8M
-$8.1M
-$6.0M
-$4.5M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your ATXS research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.